Silo Pharma, Inc. carries no debt; cash flow comfortably covers obligations.

Silo Pharma, Inc.'s free cash flow has decreased 21.58% from $-3.83M last year to $-4.66M, signaling decreasing performance

Silo Pharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Silo Pharma, Inc. has insufficient data to evaluate this check.

Silo Pharma, Inc. has a net cash position, so leverage is healthy.

Silo Pharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Silo Pharma, Inc.'s profit margin has decreased (10.26%) in the last year from -6.09K% to -6.72K%, signaling decreasing performance

Silo Pharma, Inc.'s short-term assets of $7.39M exceed its short-term liabilities of $650.18K

Silo Pharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Silo Pharma, Inc.'s return on equity of -88.41%, is lower than 15.00%, indicating bad performance

Silo Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Silo Pharma, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Silo Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Silo Pharma, Inc. has negative free cash flow, indicating cash burn

Silo Pharma, Inc.'s yearly earnings has increased -3.76% since last year from $-4.39M to $-4.23M, signaling increasing performance

Silo Pharma, Inc.'s yearly revenue has increased 0.00% since last year from $72.10K to $72.10K, signaling increasing performance

ROIC -75.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Silo Pharma, Inc.'s 3-year revenue CAGR of 0.00% is negative, indicating declining revenue over the past 3 years

Silo Pharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Silo Pharma, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Silo Pharma, Inc. has insufficient data to evaluate this check.

Silo Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Silo Pharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Silo Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Silo Pharma, Inc. has insufficient data to evaluate this check.

Silo Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Silo Pharma, Inc. has a price-to-book ratio of 0.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Silo Pharma, Inc. has a price-to-sales ratio of 47.91x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue